AbbVie reports 74% response rate for Etentamig in pivotal trial
AbbVie said Etentamig delivered a 74% overall response rate in a pivotal blood-cancer trial, while standard treatments managed 45.7%. Shares were priced at $260.445.
AbbVie NYSE:ABBV, the pharmaceutical and biotechnology giant, put its cancer pipeline squarely on investors' radar Thursday, with shares priced at $260.445.
Etentamig produced a 74% overall response rate in a pivotal blood-cancer trial.
Standard treatments managed 45.7%.
That is a massive 28.3-perc…